Uniphar on Tuesday reported increased revenue and pretax profit for 2025 as it said the trading momentum was ‘strong’ and that such a performance represents a growth rate in line with its medium-term outlook.
The Dublin-based healthcare services provider said it finished the year with a pretax profit of €71.8 million, up 17% from €61.1 million the previous year, out of total revenue rising 11% year-on-year to €3.07 billion from €2.77 billion.
Uniphar also completed its buyback programme, worth €35 million, repurchasing some 13.4 million shares, and brought the total dividend to €5.2 million, equal to 0.0202 euro cents per share, up 5.2% from last year’s €3.4 million, or 0.0131 cents per share.
The company said it is ‘well positioned to achieve continued organic gross profit profit growth in each division...and is confident of delivering on current market expectations for the full year’.
It also said it aims to grow its earnings before interest, tax, depreciation, and amortisation to €200 million by 2028, with 80% of that growth to be delivered organically, thanks to double-digit growth for its pharma division, and high single-digit growth for its medical tech division.
Uniphar reported an Ebitda of €130.9 million last year, up 6.0% from 2024’s €123.5 million.
Uniphar’s Chief Executive Officer Ger Rabbette said: ‘I am pleased with the results the group delivered in 2025, achieving our fastest rate of organic gross profit growth since IPO at 8.9%, alongside adjusted earnings per share growth of 21%. Over the past six years, we have delivered excellent compound annual adjusted EPS growth of 16%. These results reflect the successful execution of our strategy across all divisions and our continued ability to scale and generate sustainable growth.’
Uniphar shares were up 2.3% to 356.00 pence each on Tuesday morning in London.
Copyright 2026 Alliance News Ltd. All Rights Reserved.